BMY
BRISTOL MYERS SQUIBB COEvidence as of 2026-09-09The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on BMY
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · BRISTOL MYERS SQUIBB CO
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-…
Management team
- Ms. Karin Shanahan · Executive Vice President of Global Product Development & SupplyFind on LinkedIn
- Mr. Samit Hirawat M.D. · Executive VP, Chief Medical Officer & Head of DevelopmentFind on LinkedIn
- Ms. Sandra Leung Esq. · Executive VP & General CounselFind on LinkedIn
- Mr. David V. Elkins · Executive VP & CFOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.3 ) with high confidence. Revenues are non‑monotonic across the last three fiscal points: $12,222,000,000 in fiscal Q3 2025 (fiscal quarter ended 2025-10-23), $11,489,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-04-21) and $12,973,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-22). Over the same sequence reported net income rose from $2,220,000,000 to $2,677,000,000 to $3,317,000,000 and diluted EPS climbed from $1.08 to $1.31 to $1.62.
Research and development expense increased to $2,959,000,000 in fiscal Q2 2026, cash and cash equivalents declined to $8,722,000,000 as of fiscal Q2 2026, and long‑term debt fell to $42,861,000,000 on that date. Market signals are mixed: price sits above the 50‑ and 200‑day SMAs with a golden cross and strong 12‑1 momentum (+51.3%), beta is low at 0.28, and dividend yield is relatively high at 3.88%.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Reported revenues were $12,973,000,000 for fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), $11,489,000,000 for fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $12,222,000,000 for fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo); the series is not monotonic (down from Q3 2025 to Q1 2026, then up to Q2 2026).
XBRL companyfacts · 0000014272-26-000020Net income rose across the available quarters: $2,220,000,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo), $2,677,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $3,317,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0000014272-26-000020Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The Form 10-K filed 11 February 2026 (annual report for fiscal year ended 31 December 2025) adds a risk noting that, under a U.S. Government Agreement announced in December 2025, the company agreed to provide Eliquis for free to the Medicaid program effective January 1, 2026, donate more than seven tons of Eliquis API to a U.S. Strategic Active Ingredient Reserve, enable deep discounts (approximately 80% off list) for several medicines to cash-paying patients, adopt a more balanced pricing approach for new launches across developed nations, and continue to expand domestic production.
10-K filed 2026-02-11The Form 10-K filed 11 February 2026 added a risk explicitly linking the Inflation Reduction Act (IRA) to material business impact, stating the IRA has and will continue to meaningfully impact the companys business strategies and that these changes may result in a material impact on results of operations.
10-K filed 2026-02-11Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Beta vs SPY is 0.28 and correlation vs SPY is 0.13 as of 2026-09-08, indicating low market sensitivity and low co-movement with SPY on that date.
Moneyta signal set · 2026-09-08Short- and medium-term momentum are positive: 3-month momentum is +17.7% and 6-month momentum is +9.0%, with the 6-month momentum at the 52th percentile of the 548-stock research universe on 2026-09-08.
Moneyta signal set · 2026-09-08weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
The aggregated 13F-reported institutional holdings value was "$92.4M" as of 2026-03-31 (13F filings carry a 45-day reporting lag).
13F holdings · 5 filers · as of 2026-03-31M&T Bank Corp was reported as a top 13F holder with a position value of "$47.1M" in the 13F data as of 2026-03-31.
13F holdings · 5 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
On 8 September 2026, Bristol Myers Squibb issued a press release announcing positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of the GPRC5D-directed CAR T cell therapy, arlocabtagene autoleucel.
News · finance.yahoo.com · 2026-09-08A 8 September 2026 headline noted Bristol-Myers Squibb shares fell 3.2% and referenced a GuruFocus GF Score of 71.
News · gurufocus.com · 2026-09-08Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Short Bartie Wendy (EVP, Corporate Affairs) reported a transaction on 2026-09-01 recorded as "code M" for 1,236 shares with a reported value of "$83k"; the filing shows no trading plan flag.
Form 4 · Short Bartie Wendy (EVP, Corporate Affairs) · $83k code M · 2026-09-01Short Bartie Wendy (EVP, Corporate Affairs) reported a transaction on 2026-09-01 recorded as "code F" for 633 shares with a reported value of "$42k"; the filing shows no trading plan flag.
Form 4 · Short Bartie Wendy (EVP, Corporate Affairs) · $83k code M · 2026-09-01Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model shows an implied free cash flow (FCF) growth rate of 5.42% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month free cash flow (FCF) is $7,693,000,000 and FCF per share is $3.7563, based on shares outstanding around 2,042,714,656.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several contemporaneous data points jointly support a favorable read: net income and diluted EPS have risen across the last three reported quarters (fundamentals-1, fundamentals-2), while long-term debt has trended lower (fundamentals-6), and management continues to increase R&D investment (fundamentals-3). Market signals show strong longer-term momentum and technicals (market-2, market-3), a relatively high dividend yield with positive dividend growth (market-5), and recent positive clinical news around a registrational Phase 2 CAR-T trial (news-0). Valuation and cash-flow metrics imply a modest FCF growth assumption is embedded in the current price (valuation-0, valuation-1), and inclusion in SCHD plus reported insider buying provide incremental institutional and insider-engagement signals (ownership-2, insider-0, insider-1). Taken together, these items form a coherent evidentiary cluster showing improving reported profitability, deleveraging, ongoing investment in growth, supportive market momentum, and reinforcement from cash-flow based valuation.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.38
37 surviving claims rest on 14 distinct sources; the heaviest analyst carries 22% of them, and 97% of what the desk raised survived the debate.
The evidence set rests on a moderate number of distinct sources but a fairly large bundle of surviving claims, so individual sources and analysts carry meaningful influence on the read. The single heaviest analyst accounting for about a fifth of claims and a 97% survival rate through debate both suggest low internal controversy — useful for confidence but increasing fragility to single-source or analyst errors.
Peer context · computed, not argued
12-1 momentum ranks 4th of 10 in Drug Manufacturers—General (as of 2026-09-08).
6-month relative strength ranks 5th of 10 in Drug Manufacturers—General (as of 2026-09-08).
90-day volatility ranks 5th of 10 in Drug Manufacturers—General (as of 2026-09-08).
dividend yield ranks 2nd of 10 in Drug Manufacturers—General (as of 2026-09-08).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
10 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.1 to the score
6 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−1.4 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.8 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.3 to the score
5 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
2 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+0.3 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on BMY Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.